Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something isn’t right. Not being negative. Just being pragmatic.
Grip
What is not right is 95% of Wall Street cannot buy CYDY because of the new regulations set by the Broker-Dealers. So the only market is the day-traders or people who deal with very small firms like Paulson. Merrill, Wells Fargo etc. cannot buy this stock. If it's not listed on a major exchange you cannot buy with majority of dealers. They will not let new shares even on the books. THIS IS WHY CYDY IS NOT AT $10.00 a share. We have to have a partnership or buy out or we sit here...
With all the money being available for Cancer, HIV, Breast Cancer, Colon Cancer, you would think that something like Bill Gates Foundation would be all over this. If you google or twitter all of these support groups you will see many.
Michael Klump is the one who put up the 5 Million a few weeks ago. He is a Billionaire with lots of friends lives in Atlanta Ga. I am sure more cash will come.
Just a quick question for all of you that have a Medical background or have had cancer or a family member die of the dreaded disease, What if Pro140
stops cancer from metastasizing? It along with Richard G. Pestell, medicine does something even greater. The combination of the two? Maybe I am confused with the track here but I think we might have a miracle drug in our mist! Can you believe we are all apart of this? I think this month of August will be amazing.
Any thoughts why the CEO and President of Gilead resigned yesterday?
Read this site
www.bcrf.org
My broker sent to me.. Every 2 minutes a woman in the US is diagnosed with Breast Cancer!
That is 262,800 new cases a year
“I contacted CytoDyn last year about conducting studies with PRO 140 in metastatic breast and prostate cancer after my published research, and studies by others, had shown promising results with small molecule CCR5 antagonists in multiple cancer indications,” said Dr. Pestell
Prostate is next!!!!! Etc Etc
This guy is extremely respected in the field of medicine.
https://en.wikipedia.org/wiki/Richard_Pestell
THANK YOU SO MUCH GESTALT GREAT WORK
Nicely put Searching4rainbow
totally agree
Just hang in there it will happen
Grip only had 6000 shares I thought
Grip
I think we have more news coming. I bet we have a conference call next week that should be very interesting. I visited my Prophet last night and feel much better.
Check out SRPT today, I remember when it was priced in line with CYDY.
save
saved
by Molly Walker, Staff Writer, MedPage Today
June 11, 2018
This article is a collaboration between MedPage Today® and:
ATLANTA -- The addition of PRO 140 SC, a subcutaneous injection of a monoclonal antibody, to an existing HIV drug treatment regimen was effective at reducing viral load in previously treated HIV patients, a late-breaking trial presented here found.
An ongoing phase IIb/III efficacy trial found that a significantly higher proportion of patients treated with PRO 140 had a 0.5 log10 or greater reduction in viral load compared with patients treated with placebo (64% versus 23%, P=0.0032), reported Kush Dhody, MBBS, of Amarex Clinical Research in Washington, D.C., and colleagues at the ASM Microbe annual meeting.
PRO 140, which has FDA Fast Track status, is a humanized IgG4 monoclonal antibody that binds to the C-C motif chemokine receptor 5 gene (CCR5). "In patients infected exclusively with CCR5-topic HIV-1, the therapy showed antiviral activity of ≥1.65 log10 mean viral load reduction as a weekly subcutaneous injection," the researchers reported.
Along with ibalizumab, PRO 140 is one of two monoclonal antibodies for treating HIV that have recently shown promise in previously treated HIV patients.
At a poster presentation at the meeting, Dhody told MedPage Today that this new option would be particularly useful for HIV patients with resistance to drugs, because such patients have "limited options to construct a new regimen."
Those enrolled in the study had to be previously treated adults (defined as having a documented resistance to at least one antiretroviral therapy (ART) within three drug classes or within two drug classes and have limited treatment options), with exclusive R5-tropic virus and a viral load of ≥400 copies/mL.
Overall, 52 subjects were randomized to receive either PRO 140 350 mg subcutaneously, along with their existing combination ART for 1 week. Patients were a median 53 years old, and almost three-quarters were men. About 52% were white and 46% were black, with a median 21-year duration of HIV infection. Patients were treated with a mean number of 11 ART drugs prior to enrollment in the study, with resistance to nine.
Because patients on the treatment had a significant reduction in HIV-1 copies/mL (P<0.001 in intent-to-treat population), the primary outcome was met. Overall, 32 patients completed the study, with 17 ongoing and three who discontinued the study early.
There were 32 patients who had at least one adverse event, but none discontinued treatment due to these adverse events. A separate safety study of PRO 140 is ongoing, which examines the treatment as a monotherapy, "where patients stop their current therapy and receive a once-a-week supplemental injection," Dhody said.
In addition, he said, the company has a meeting scheduled with the FDA later this month to discuss the product license application summation, where this research and the safety data will be presented. After that, Dhody said, the plan is to determine the submission strategy.
Dhody is an employee of Amarex Clinical Research, LLC.
Other co-authors reported employment with Amarex or CytoDyn Inc., and support from CytoDyn and Progenics.
Primary Source
ASM Microbe
Source Reference: Dhody K, et al "Primary efficacy results of PRO 140 SC in a pivotal phase 2b/3 study in heavily treatment-experienced HIV-1 patients" ASM Microbe 2018; Abstract AAR LB15-SATURDAY.
Comment
Amatuer17 thank you for your updates on CYDY
https://www.medpagetoday.com/meetingcoverage/asmmicrobe/73424
read the last paragraph about the meeting with the FDA
Thank you so much for your encouragement and FYI the meeting with the FDA is tomorrow. I believe we will have many updates in the next few days.
Amatuer17
Nadar and the team would not be going to the meeting tomorrow in Maryland if it was not complete. If you remember the meeting was scheduled earlier but FDA wanted more information and my Intel says we are more than ready.
I believe that the next two weeks are going to be incredible for all of us.
What we have is not just HIV, it is much bigger. Amatuer17 please know that you do not know all the facts.
My bad!!!!
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily treatment-experienced HIV-1 patients will be presented in a Late-Breaker Abstract poster session at ASM Microbe on Saturday, June 9, in Atlanta. The trial results detail data from the one-week, single-dose, randomized, double-blind, placebo-controlled portion of the pivotal trial of PRO140 in combination with optimized background anti-retroviral therapy (ART).
Session 226: Late Breaker Abstract poster session
Title: “Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients”
Date: Saturday June 9
Time: 11:00 am - 1:00 pm ET
Location: Exhibit and Poster Hall, Building B, Halls B2-B5
Georgia World Congress Center
Control/Tracking Number: 2018-LB-7818-MICROBE
I might be wrong but it's today not this weekend
Thursday (6/7): ASM Microbe Meeting, Atlanta, GA (5 days). CytoDyn (OTCQB:CYDY): Phase 2b/3 data on Pro 140 in HIV-1.
Tomorrow is the big day in Atlanta,
https://seekingalpha.com/news/3359737-key-events-next-week-healthcare#email_link
Thursday (6/7): ASM Microbe Meeting, Atlanta, GA (5 days). CytoDyn (OTCQB:CYDY): Phase 2b/3 data on Pro 140 in HIV-1.
Also, I think it ends the 60th day that we applied for the breakthrough designation on or around )4/06/2018
https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm
Key events next week - healthcare
Jun. 1, 2018 11:18 AM ET|By: Douglas W. House, SA News Editor
Noteworthy events during the week of June 3 - 9 for healthcare investors.
Sunday (6/3): Associated Professional Sleep Societies Annual Meeting (SLEEP), Baltimore, MD (4 days). Jazz Pharmaceuticals (NASDAQ:JAZZ): 20 abstracts across sleep portfolio.
Monday (6/4): TherapeuticsMD (NYSEMKT:TXMD): Investor & Analyst Day, NYC.
Bristol-Myers Squibb (NYSE:BMY): ASCO Investor Event (8:30 pm ET).
Wednesday (6/6): European Cystic Fibrosis Conference, Belgrade (4 days). Eloxx Pharmaceuticals (NASDAQ:ELOX): ELX-02 data.
Thursday (6/7): ASM Microbe, Atlanta, GA (5 days). CytoDyn (OTCQB:CYDY): Phase 2b/3 data on Pro 140 in HIV-1.
His whole Life was Pro140 his family would never sell
https://www.huffingtonpost.com/gordy-grundy/hivaids-researcher-allen-_b_7764756.html
Interesting Post Searching
Perhaps an estate gifted shares to an institution or another beneficiary and they liquidated upon receiving the gift.
I have had that happen to me many times in the past 40 years in this business, Mother dies and all kids can think of is my share of the rainbow.
Had AOL at $4.00 it ran to $130.00 begged them to hold but he needed his cigs
I still think it's shorts
If we spit a week from Thursday this short position has to cover within a day
http://otce.finra.org/ESI
Now on 3/15/18, we were 684,000 short and with yesterday it is probably 2 million short now,
Should be interesting, I am not selling any of mine to them. The rules on the NYSE are more strict and regulated. 99% of all brokers, hedge funds, mutual funds, exchange funds etc cannot buy on this current Board OTCBB.
The split could not come soon enough because I going back in big time. I never want to see the OTCBB again....EVER
I totally agree that the Company is under an NDA and someone is in doing their due diligence, remember that we will know the reverse split number a week from today. I would tend to think that more news will come any day and it will be positive. I am going out on a limb here and predict a buyout of the HIV portion. We still have GVHD. On a positive note for the shorts, they will have to automatically cover when we move to the new Board. That is a rule because they get a new cusip number.
From what I understand we will know the ratio on the 17th and split will occur on the 19th
Suvorov
By the time you get your shares, this game will be over and we will be on to another venture.
That is really an IGNORANT quote. I have been in the INVESTMENT business for 40 years and that has never happened if you were with a firm that had SIPC coverage. If you take the shares you cannot sell in 15 minutes like if they were held at a firm. OTCB is a nightmare with firms.
See below
https://budgeting.thenest.com/lose-shares-broker-goes-bankrupt-23338.html
NEVER HEARD OF WHAT YOU ARE SAYING IN 40 YEARS.
Remember that when you up list to a new exchange like NYSE Cytodyn will get a new Cusp number which is nine characters. What is fun is that all short positions will have to cover immediately.
Take a minute to read why the OTCBB is so corrupt
http://www.hawkassociates.com/pdf/uploads/Eat_My_Shorts.pdf
Or try this
http://www.hawkassociates.com/ir/white/shorts.cfm
What is naked shorting and why should a CEO care?
In its simplest terms, naked shorting involves selling shares of stock that don't exist. It's performed routinely by market-makers to keep an orderly market, but it is illegal when done to manipulate a company's stock price. Only when someone intends to drive down the stock price is naked shorting breaking the law. Throughout the rest of this overview, any reference to naked shorting will refer to the illegal variety.
I BET CYDY HAS MILLIONS OF NAKED SHORTS. READ THE ABOVE ARTICLE
JUST WAIT TILL THEY ALL HAVE TO COVER.. long cydy
I am for a reverse if it makes sense. Move the same day no short attack. But I think if we get approved for monotherapy we are off to the races.
We will not need a reverse split. My opinion only, thank you for researching my post, you are deff doing your client well.
Gestalt
You are right on!!!!!!!!!
I am going out on a limb here and say I bet that we do not do a split.
Don't ask why just have a wonderful weekend.
She wants me to play, "Devil's Advocate", so here I am.
He is the Devil be careful
I am just curious what most of you think about what is going on, I think everything is about GVHD and not so much about HIV. I have no way of knowing but feel like we will have a reverse split very soon.
Thoughts
NM
From my broker last night
In 2001, NIH National Institutes of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci estimated that annual autoimmune disease treatment costs were greater than $100 billion.
http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/new-challenges-opportunities-autoimmune-disease-treatment
What is CYDY worth now to BP
BULLMARKET713
I think you are right on the money with your post. I have a feeling more to come
“One FDA official told me ‘I have a room full of adolescents right now that would love this,’ and that is a direct quote,” Pourhassan said. “Treatment interruption is very attractive for the patient.”
Pourhassan said if the product comes to market, CytoDyn likely will be acquired by a large drug manufacturer such as Gilead. He said the company already met with a Gilead representative a while back, but at that time PRO 140 only was on track to win FDA approval for use among people who inject drugs and do not adhere to traditional regimens.
If we are right about CYDY and Pro140 would PGNX be a good play?
See below
the terms of the Agreement provide for an initial payment by the Company to Progenics in the amount of $3.5 million and subsequent milestone payments conditioned on successful continued clinical development of PRO 140 and a royalty payment to Progenics based on net sales upon commercialization following final FDA approval. The closing of this transaction is currently expected to take place in the next 90 days, but is subject to the satisfaction of a number of closing conditions, including, among other matters: (i) Progenics having received all required authorizations, consents and approvals of government authorities; (ii) Progenics having entered into and delivered intellectual property assignments; (iii) the Company and Progenics having entered into a transition services agreement; (iv) the Company having obtained the financing and raising of capital it needs in order to consummate the transactions contemplated by the Agreement; and (v) the Company having completed and been satisfied with its continuing due diligence investigation of PRO 140.